INCATE supports innovators
to fight drug-resistant bacterial infections
Our Mission
Supporting innovators to fight drug-resistant infections
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Whats up?
Latest News
The INCATE Selection Committee has chosen four new ventures for Stage I support. Meet the latest additions to the INCATE family: Adina Technologies – This project aims to enhance infection control in prosthetic devices by [...]
Did you know phages helped stop a cholera outbreak in Stalingrad during WWII? While antibiotics [...]
In 2025, it is possible — and increasingly common — to treat cancer but lose [...]
At INCATE, we are committed to providing support to early-stage innovators working on antimicrobial resistance [...]
On February 7, 2025, Swiss biopharmaceutical innovator BioVersys made its debut on the SIX Swiss [...]
What we do
Supporting your venture
Advice
Advice from partners, including Industry, to enable; early alignment with medical needs and market demand, the development of a quality translational path and a plan to build a company.
Community
Access to a community of engaged individuals across industry, academia, entrepreneurs, policymakers, investors, public health and healthcare providers to share ideas and fight drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
